An AMS team of experts at your disposal, working together to plan, initiate and execute your clinical development program from Phase I-IV to approval and non-interventional studies to post-authorization studies.
AMS offers global strategy and support around ever-evolving regulatory requirements. Our AMS regulatory affairs experts have extensive knowledge and experience, and will partner with you every step of the way.
Make meaningful and data-driven decisions with the help of our in-house biostaticians, data managers and innovative technologies.
The AMS Clinical Safety Team can provide you with a full safety service range or a custom-made single service package according to your needs.
We provide successful strategies for European Market Access, HTAs, Early Benefit Access, and AMNOG submissions to bring your drugs or devices to market.
AMS has an outsourced field sales team who will partner alongside you and help you to provide information to support prescribers and patients.
We are the “Team Company” – a team of experts, who provides a committed, collaborative and quality-focused approach to our Life Science companies. Our highest priority is to help bring your product to patients in the fastest, most effective way possible.
“With AMS, we have found a reliable partner. The cooperation is characterized by high professionalism, quality and flexibility.” - Boehringer IngelHeim
“AMS is always a reliable partner.” - Pfizer Germany GmbH
“AMS is not only characterized by reliability and care with excellent expertise, but above all, by a pronounced sense of responsibility and high-quality standards. After many years of successful collaboration, AMS is clearly a partner of the very first choice in creating the dossier for early benefit assessment.” - Gilead Sciences GmbH
AMS will lead and deliver the highest quality in your project implementation process.
It’s our focus to achieve regulatory success in guiding and supporting the right pathway for your program.
We’re the leading service provider in early benefit assessment, European HTAs and Market Access.
